We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cautious optimism surrounds early clinical data for PD-1 blocker.
- Authors
Sheridan, Cormac
- Abstract
The article provides information on the results of a clinical trial conducted by Bristol-Myers Squibb Co. and its partner Ono Pharmaceuticals Co. Ltd. that demonstrates about a new class of drugs that block the programmed cell death 1 (PD-1) receptor. The results show that fully human IgG4 monoclonal antibody (mAb) drug BMS-936558 can elicit responses in highly refractory cancers. The study also found an association between response to therapy and the PDL-1 status of patients' tumors.
- Subjects
CLINICAL trials; BRISTOL-Myers Squibb Co.; ONO Pharmaceutical Co. Ltd.; DRUG efficacy; THERAPEUTIC use of monoclonal antibodies; APOPTOSIS
- Publication
Nature Biotechnology, 2012, Vol 30, Issue 8, p729
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0812-729